Announcement PDF RNS Number : 2911E Shield Therapeutics PLC 28 June 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results of 2023 Annual General Meeting London, UK, 28 June 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/ Feraccru® (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2023. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below. The following table shows the votes cast on each resolution: % Resolution 1 VOTES FOR 119,538,439 VOTES AGAINST % 98.78% 1,475,717 1.22% WITHHELD VOTES 77,639 Resolution 2 104,595,075 86.45% 16,390,220 13.55% 106,500 Resolution 3 119,472,808 98.75% 1,512,487 1.25% 106,500 Resolution 4 118,885,249 98.26% 2,100,046 1.74% 106,500 Resolution 5 119,959,907 99.15% 1,025,388 0.85% 106,500 Resolution 6 120,578,657 99.66% 407,538 0.34% 105,600 Resolution 7 119,046,402 98.40% 1,938,893 1.60% 106,500 Resolution 8 120,575,411 99.64% 437,845 0.36% 78,539 Resolution 9 119,859,760 99.06% 1,143,185 0.94% 88,850 Resolution 10 118,585,474 97.99% 2,433,532 2.01% 72,789 Resolution 11 Resolution 12 117,131,887 96.78% 3,892,308 3.22% 67,600 116,917,813 96.61% 4,106,382 3.39% 67,600 Notes: 1. Number of shares in issue 713,036,342. 2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/. 3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. For further information please contact: Shield Therapeutics plc Greg Madison, CEO Hans-Peter Rudolf, CFO Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Oliver Duckworth Joint Broker finnCap Ltd www.shieldtherapeutics.com +44 (0) 191 511 8500 +44 (0)20 7418 8900 +44 (0)20 7220 0500 Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks Financial PR & IR Advisor Walbrook PR Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com About Accrufer®/Feraccru® Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com About Shield Therapeutics plc Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s Accrufer®/Feraccru® are registered trademarks of the Shield Group This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGZZGZVVRMGFZM